Generic version of a drug already on the market, which can suppress and prevent HIV, would still yield 30% profit if the current price was slashed, researchers say

Lenacapavir , sold as Sunlenca by US pharmaceutical giant Gilead, currently costs $42,250 for the first year. The company is being urged to make it available at a thousand times less than that price worldwide.

UNAids said it could “herald a breakthrough for HIV prevention” if the drug was available “rapidly and affordably”.

Given by injection every six months, lenacapavir can prevent infection and suppress HIV in people who are already infected.

In a trial, the drug offered 100% protection to more than 5,000 women in South Africa and Uganda, according to results announced by Gilead last month.

  • coyotino [he/him]@beehaw.orgEnglish
    9·
    3 months ago

    so much of it is paid with grants anyway, I don’t think pharma companies should keep any profits unless they fund 100% of the r&d for it, which they won’t

    This is a strong point. If so much of this R&D is government-funded, then why tf are the drug companies allowed to profit from it? Corporate welfare is America’s only real welfare problem.